|
|
Anavex presents data on neuroprotective evidence for ANAVEX 2-73, lead compound for Alzheimer's disease
Sources News Release
http://www.sources.com/Releases/NR1383.htm
Publisher: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Date Written: 26/07/2011
Year Published: 2011
Resource Type: Article
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled Preclinical development of new tetrahydrofur
Abstract: Hoboken, NJ – July 26, 2011 -- Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, entitled “Preclinical development of new tetrahydrofuran derivatives targeting the sigma-1 chaperone protein as neuroprotectants in Alzheimer’s disease.”
Neuroprotective, anti-amnesic, anti-depressive and anti-convulsive effects have previously been described with a ne...
To read the full release go to http://www.sources.com/Releases/NR1383.htm
Topics
|
AlterLinks
c/o Sources
© 2025.
|
|
|
|
